Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarwyn Val. Regulatory News (MVI)

Share Price Information for Marwyn Val. (MVI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 96.00
Bid: 95.00
Ask: 97.00
Change: 0.50 (0.52%)
Spread: 2.00 (2.105%)
Open: 95.50
High: 96.00
Low: 95.50
Prev. Close: 95.50
MVI Live PriceLast checked at -
Marwyn Value Investors is an Investment Trust

To achieve long-term capital appreciation through its investment in the Master Fund primarily by focusing in mid cap businesses headquartered in the UK, Europe or North America.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Settlement of VAT Reclaim

7 Nov 2022 07:01

RNS Number : 4518F
Marwyn Value Investors Limited
07 November 2022
 

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OR ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

LEI: 213800L5751QTTVEA774

 

7 November 2022

 

 

Marwyn Value Investors Limited

Update on Settlement of VAT Reclaim

 

Further to the Company's announcement on 10 August 2022, the Company is pleased to announce that a further Praesepe VAT reclaim in which the Master Fund has an interest has now been agreed by HMRC.

 

Whilst the total amount attributable to the Master Fund and deductions including fees, tax and other expenses are yet to be finalised, it is expected that cash in excess of £3 million will be received by the Master Fund in the coming weeks, of which, approximately 86.3% will be attributable to the Company's ordinary shareholders, approximately 10.6% will be attributable to the Company's 2016 realisation shareholders and approximately 0.6% will be attributable to the Company's 2021 realisation shareholders. This will be recognised in the Company's estimated net asset value from the date on which the amount is finalised.

 

A further announcement will be made confirming the final cash amounts in due course.

 

Potential Future Claims

Including the above claim and the amounts already received by the Master Fund, net of fees, tax and other expenses (being £1.06 million received in August 2022 and £0.29 million received in September 2022), approximately 50% of the total gross claims in which the Master Fund has an interest have now been agreed by HMRC.

 

Whilst it is expected that the remaining claims will be settled in an equivalent manner, there remains significant uncertainty over both the amount that may be repaid by HMRC and the timing of receipt of any cash, net of fees, taxes and other expenses by the Master Fund. Accordingly, no amount relating to the remaining claims will be reflected in the Company's estimated NAV calculations which are reported via RNS until there is sufficient certainty over the amount and timing of the receivable, at which point a further RNS announcement will be made.

 

 

Company enquiries:

Aztec Financial Services (Jersey) Limited

Chris Copperwaite / Magdala Mullegadoo

Telephone: 01534 833000

 

Investor Relations

Kam Bansil

Telephone: 020 7039 1901

 

Corporate Broker - Liberum Capital Limited

Chris Clarke / Owen Matthews

Telephone: 0203 100 2200

 

Marwyn Value Investors Limited is a closed-ended investment company on the London Stock Exchange Specialist Fund Segment - a fully regulated market for professional, institutional and sophisticated investors. Marwyn's previous 11 comparable listed acquisition companies which have completed a platform acquisition have delivered in excess of £4.2 billion in equity profits and an aggregate return on capital to shareholders of 119 per cent (as at 31 October 2022).

For further information see http://www.marwynvalue.com. Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This announcement includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "expects", "believes", "estimates", "envisages", "plans", "anticipates", "targets", "aims", "continues", "expects", "intends", "hopes", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not facts. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. A number of factors could cause actual results and developments to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this announcement based on past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Subject to any requirement under the Listing Rules, Prospectus Rules, the Disclosure Guidance and Transparency Rules or other applicable legislation or regulation, the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBQLLBLFLZFBF
Date   Source Headline
1st May 20247:00 amRNSInterim Dividend to Ordinary Shareholders
30th Apr 20242:56 pmRNSShare Dealings
30th Apr 20247:00 amRNSAnnual Financial Statements December 2023
22nd Apr 202411:00 amRNSNet Asset Values
15th Apr 202411:00 amRNSNet Asset Values
9th Apr 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
9th Apr 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
9th Apr 202410:00 amRNSNet Asset Value - Ordinary Shares
28th Mar 20243:26 pmRNSShare Transfer
21st Mar 20243:53 pmRNSNotification of Major Interests in Shares
21st Mar 20243:51 pmRNSNotification of Major Interests in Shares
20th Mar 20241:42 pmRNSShare Transfer
18th Mar 202411:00 amRNSNet Asset Values
11th Mar 202411:00 amRNSNet Asset Values
7th Mar 20241:52 pmRNSNotification of Major Interests in Shares
4th Mar 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
4th Mar 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
4th Mar 202410:00 amRNSNet Asset Value - Ordinary Shares
28th Feb 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
28th Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
28th Feb 202410:00 amRNSNet Asset Value - Ordinary Shares
23rd Feb 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
23rd Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
23rd Feb 202410:00 amRNSNet Asset Value - Ordinary Shares
14th Feb 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
14th Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Feb 202410:00 amRNSNet Asset Value - Ordinary Shares
2nd Feb 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
2nd Feb 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
2nd Feb 202410:00 amRNSNet Asset Value - Ordinary Shares
26th Jan 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
26th Jan 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
26th Jan 202410:00 amRNSNet Asset Value - Ordinary Shares
25th Jan 20247:00 amRNSInterim Dividend to Ordinary Shareholders
15th Jan 202410:10 amRNSNet Asset Value - 2021 Realisation Shares
15th Jan 202410:05 amRNSNet Asset Value - 2016 Realisation Shares
15th Jan 202410:00 amRNSNet Asset Value - Ordinary Shares
29th Dec 202310:10 amRNSNet Asset Value - 2021 Realisation Shares
29th Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
29th Dec 202310:00 amRNSNet Asset Value - Ordinary Shares
22nd Dec 202310:10 amRNSNet Asset Value - 2021 Realisation Shares
22nd Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
22nd Dec 202310:00 amRNSNet Asset Value - Ordinary Shares
18th Dec 20235:53 pmRNSShare Dealings
15th Dec 202311:42 amRNSNotification of Major Interests in Shares
14th Dec 20231:02 pmRNSResult of AGM
14th Dec 202310:10 amRNSNet Asset Value - 2021 Realisation Shares
14th Dec 202310:05 amRNSNet Asset Value - 2016 Realisation Shares
14th Dec 202310:00 amRNSNet Asset Value - Ordinary Shares
12th Dec 202311:50 amRNSNotification of major interests in shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.